Back to Screener

Healthcare

JCR Pharmaceuticals Co., Ltd.(JCRRF)

Live Price

Offline

$3.15

+0.00% today

1Y Change

-16.80%

Window

Jun 27, 2025 โ†’ Jun 19, 2026

Market Cap
$66.24B
Revenue Growth
-22.9%
EPS Growth
-187.1%
Dividend Yield
3.7%

Coverage: 251 bars ยท Jun 27, 2025 โ†’ Jun 19, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

JCR Pharmaceuticals Co., Ltd. (JCRRF) is a Healthcare stock with a market cap of $66.24B and listed on OTC. The stock last traded around $3.15 and down 16.8% across the available one-year price window (Jun 27, 2025 โ†’ Jun 19, 2026). Baseline metrics include revenue growth of -22.9%, EPS growth of -187.1%, a dividend yield of 3.7%. What stands out right now is revenue -22.9%, EPS -187.1%, free cash flow -313.0% with operating margin -15.0% and ROIC -4.1%. The dividend matters to the case here, with a current yield around 3.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines JCRRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

JCRRF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

JCRRF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

JCRRF Max Drawdown

-37.10%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for JCRRF and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for JCRRF

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.